Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.

被引：37

作者：

Chiappori, Alberto

Williams, Charles C.

Creelan, Ben C.

Tanvetyanon, Tawee

Gray, Jhanelle Elaine

Haura, Eric B.

Thapa, Ram

Chen, Dung-Tsa

Beg, Amer A.

Boyle, Theresa A.

Bendiske, Jennifer

Morris, Erick

Tao, Aiyang

Hurtado, Felipe K.

Manenti, Luigi

Castro, Julio

Antonia, Scott Joseph

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL USA

[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Biostatist, Tampa, FL USA

[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL USA

[5] Novartis Inst Biomed Res, Translat Clin Oncol, E Hanover, NJ USA

[6] Novartis Inst Biomed Res, Oncol Translat Res, Cambridge, MA USA

[7] Novartis Inst Biomed Res, Early Clin Biostatist, E Hanover, NJ USA

[8] Novartis Inst Biomed Res, Oncol Clin Pharmacol, E Hanover, NJ USA

[9] Palobiofarma SL, Navarra, Spain

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.9089

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9089

引用

页数：1